Trial
NCT04524689
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Intervention
SAR408701 (Tusamitamab ravtansine)
Why stopped
Sponsor decision, the decision is not related to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-29